China Regenerative Medicine International Limited (HK:8158)
:8158
Top Page
China Regenerative Medicine International Limited
(8158)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$0.37
▼(-9.27% Downside)
Action:ReiteratedDate:01/21/26
The score is held down primarily by weak financial quality (high leverage and zero operating/free cash flow in 2024) despite improved profitability. Technicals are also bearish with price below key moving averages and negative MACD, though momentum appears oversold. Valuation is only neutral (P/E 21.43) and does not offset the financial and technical risks.
Positive Factors
Gross margin expansion
A large jump in gross margin suggests meaningful improvement in cost of goods sold or pricing power, which enhances long-term profitability potential. Sustained higher gross margins provide a structural cushion to absorb R&D and SG&A, improving chances to fund growth without continual capital raises.
Negative Factors
High leverage
Elevated leverage materially reduces financial flexibility and increases interest and refinancing risk, particularly for a biotech that may require sustained R&D and commercialization spend. High debt amplifies downside in revenue shortfalls and can constrain strategic options over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin expansion
A large jump in gross margin suggests meaningful improvement in cost of goods sold or pricing power, which enhances long-term profitability potential. Sustained higher gross margins provide a structural cushion to absorb R&D and SG&A, improving chances to fund growth without continual capital raises.
Read all positive factors
China Regenerative Medicine International Limited (8158) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$94.32M
Dividend YieldN/A
Average Volume (3M)55.39K
Price to Earnings (P/E)4.6
Beta (1Y)-0.15
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.07
Shares Outstanding304,252,470
10 Day Avg. Volume53,325
30 Day Avg. Volume55,386
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.56
Price to Sales (P/S)0.99
P/FCF Ratio5.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Regenerative Medicine International Limited Business Overview & Revenue Model
Company Description
China Regenerative Medicine International Limited, an investment holding company, produces and sells healthcare products and services. The company offers health management services, such as assessment of health situation, treatment for detox, bala...
How the Company Makes Money
The company generates revenue primarily through the commercialization of its regenerative medicine products and therapies, which include stem cell treatments and related medical services. Key revenue streams include sales from its proprietary ther...
China Regenerative Medicine International Limited Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
35
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.22M | 90.62M | 69.49M | 41.54M | 282.90M | 182.14M |
| Gross Profit | 36.05M | 57.65M | 19.42M | 37.62M | 67.73M | 41.81M |
| EBITDA | -13.31M | 29.84M | -95.40M | 14.44M | 65.11M | -122.46M |
| Net Income | 5.53M | 17.75M | -107.70M | 4.55M | 51.83M | -404.23M |
Balance Sheet | ||||||
| Total Assets | 157.90M | 135.71M | 185.90M | 275.91M | 259.14M | 152.49M |
| Cash, Cash Equivalents and Short-Term Investments | 7.28M | 57.45M | 3.33M | 1.85M | 9.93M | 4.77M |
| Total Debt | 76.05M | 53.69M | 50.19M | 72.01M | 35.82M | 43.19M |
| Total Liabilities | 128.84M | 110.51M | 174.10M | 172.00M | 147.41M | 207.64M |
| Stockholders Equity | 29.06M | 25.20M | 11.79M | 103.92M | 111.73M | 58.13M |
Cash Flow | ||||||
| Free Cash Flow | 2.35M | 17.68M | 6.06M | -20.25M | -3.83M | -397.74M |
| Operating Cash Flow | 2.98M | 18.30M | 6.34M | -17.65M | -3.02M | -397.74M |
| Investing Cash Flow | -92.00K | -622.00K | -262.00K | -2.59M | 9.27M | 326.96M |
| Financing Cash Flow | -3.27M | 2.37M | -7.36M | 7.32M | -1.39M | 67.37M |
China Regenerative Medicine International Limited Technical Analysis
Negative
0.41
Price Trends
0.34
Negative
0.41
Negative
0.55
Negative
Market Momentum
>-0.01
Negative
46.49
Neutral
33.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8158, the sentiment is Negative. The current price of 0.41 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.34, and below the 200-day MA of 0.55, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.49 is Neutral, neither overbought nor oversold. The STOCH value of 33.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8158.
China Regenerative Medicine International Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$619.54M | 2.22 | 25.79% | 2.37% | 15.97% | -3.77% | |
52 Neutral | HK$3.74B | -13.26 | 11.40% | ― | 79.98% | -3.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.34B | 0.95 | 8.92% | ― | -40.24% | 66.43% | |
44 Neutral | HK$758.18M | -6.45 | 191.92% | ― | ― | 83.89% | |
43 Neutral | HK$1.23B | -2.47 | -27.44% | ― | -57.84% | 24.58% | |
41 Neutral | HK$94.32M | 4.64 | 88.62% | ― | ― | ― |
* Healthcare Sector Average
HK:8158
China Regenerative Medicine International Limited
0.31
-0.05
-13.89%
HK:0690
Uni-Bio Science Group Ltd.
0.10
0.04
65.08%
HK:1228
CANbridge Pharmaceuticals Inc.
2.63
2.49
1778.57%
HK:2197
Clover Biopharmaceuticals Ltd.
2.88
2.67
1271.43%
HK:2257
Sirnaomics Ltd.
6.91
3.81
122.90%
HK:6628
Transcenta Holding Limited
2.79
1.68
151.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.